Ricoh released its FY2025 financial results (fiscal year ended March 31, 2026). Here is the recap for the camera and imaging business listed under “other”:
- Cameras performed well and increased earnings, primarily driven by the Ricoh GR series.
- The segment overall reduced its operating loss through cost controls and robust camera sales, despite upfront investments in new businesses and a goodwill impairment in the drug discovery support business.
Camera Division Information
Ricoh’s camera business (Ricoh GR series digital cameras, Pentax cameras, 360° cameras, etc.) is not a standalone segment. It falls under the “Other” segment (which also includes environment, healthcare, drug discovery support, Smart Vision B2B solutions, and new business initiatives). Cameras are not part of the “Digital Products” segment (which covers MFPs, printers, scanners, and related OEM/production).
“Other” Segment Results (FY2025, external sales)
- Sales: ¥43.1 billion (+20.3% YoY)
- Operating loss: ¥(3.3) billion (improved ¥2.2 billion YoY)
Ricoh said the “Other” segment still posted an operating loss overall because of:
- Upfront investment in new businesses
- Goodwill impairment losses related to drug-discovery support operations
What this means:
- Ricoh GR remains the core driver of Ricoh’s entire camera business.
- Pentax remains strategically quiet in Ricoh’s official reporting – no revenue, unit, or performance commentary.
- Ricoh’s camera division is profitable and growing, but entirely GR‑led according to FY2025 disclosures.
